CytomX Therapeutics (CTMX)
(Delayed Data from NSDQ)
$1.45 USD
+0.07 (5.07%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $1.45 0.00 (0.00%) 6:16 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
CytomX Therapeutics (CTMX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$5.77 | $8.00 | $3.50 | 318.12% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for CytomX Therapeutics comes to $5.77. The forecasts range from a low of $3.50 to a high of $8.00. The average price target represents an increase of 318.12% from the last closing price of $1.38.
Analyst Price Targets (4 )
Broker Rating
CytomX Therapeutics currently has an average brokerage recommendation (ABR) of 1.86 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.86 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, four are Strong Buy, representing 57.14% of all recommendations. A month ago, Strong Buy represented 57.14%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 3 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 4 | 6 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.86 | 1.86 | 1.86 | 2.14 | 2.71 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/9/2024 | Wedbush Securities | Robert Driscoll | Hold | Strong Buy |
5/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/9/2024 | H.C. Wainwright & Co. | Mitchell S Kapoor | Hold | Hold |
5/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/12/2024 | BMO Capital Markets | Etzer Darout | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.86 |
ABR (Last week) | 1.86 |
# of Recs in ABR | 7 |
Average Target Price | $5.77 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | -0.07 |